NCT05894265
Recruiting
N/A
Prospective Pilot Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (Active Matrix) vs. Standard of Care in Arthroscopic Rotator Cuff Repair
The University of Texas Health Science Center, Houston2 sites in 1 country72 target enrollmentJune 14, 2023
ConditionsRotator Cuff Tears
Overview
- Phase
- N/A
- Intervention
- ActiveMatrix® Dosage A
- Conditions
- Rotator Cuff Tears
- Sponsor
- The University of Texas Health Science Center, Houston
- Enrollment
- 72
- Locations
- 2
- Primary Endpoint
- Change in Sugaya score as measured by Magnetic Resonance Imaging (MRI)
- Status
- Recruiting
- Last Updated
- 3 days ago
Overview
Brief Summary
The purpose of this study is to see how well the ActiveMatrix® graft works at improving healing and function of the shoulder following rotator cuff repair surgery
Investigators
Eric F Berkman
Assistant Professor
The University of Texas Health Science Center, Houston
Eligibility Criteria
Inclusion Criteria
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •1-2 tendon full thickness reparable rotator cuff tendon tear(s)
- •Reparable tear defined as:
- •a tear of the rotator cuff where it is possible to bring the retracted tendon edge back to the greater tuberosity of the humerus under minimal tension.
- •Full-thickness tear defined as:
- •a tear that involves the majority of supraspinatus and less than half of the infraspinatus under minimal tension, with no subscapularis involvement beyond the upper border
- •Failed conservative medical management of the rotator cuff tendon tear defined as: 4-6 weeks of formal physical therapy or guided home exercises and activity modification
- •Have no contraindications or allergies to the treatment administered
- •Have current imaging studies (plain radiographs and MRI exams) of the shoulder to rule out other etiologic diagnoses
Exclusion Criteria
- •Prior surgery on the index shoulder within 12 months of enrollment, including Latarjet procedures, superior labral treat from anterior to posterior (SLAP), and (failed) primary rotator cuff surgery,
- •Prior surgery for bone defects requiring bone implantation in the index shoulder,
- •Steroid injection into the index shoulder within 6 weeks of enrollment.
- •Subscapularis tear greater than 1/3 of tendon involvement requiring repair,
- •Calcific tendonitis in the index shoulder,
- •Fatty infiltration of the index shoulder rotator cuff muscle, i.e. Goutallier classification ≥ Grade 3,
- •Contralateral shoulder injury that may interfere with the post-operative rotator cuff repair rehab guidelines,
- •History of advanced osteoarthritis of glenohumeral joint (AC joint can have advanced OA) i.e. Samilson-Prieto classification ≥ Grade 2
- •History of malignant tumor and osseous metastatic disease,
- •History of heterotopic ossification,
Arms & Interventions
ActiveMatrix® Dosage A
Intervention: ActiveMatrix® Dosage A
ActiveMatrix® Dosage B
Intervention: ActiveMatrix® Dosage B
Saline Injection
Intervention: Saline injection
Outcomes
Primary Outcomes
Change in Sugaya score as measured by Magnetic Resonance Imaging (MRI)
Time Frame: 6 months post surgery , 12 months post surgery
Sugaya classification is a classification system that is used to analyze postoperative rotator cuff tendon integrity
Secondary Outcomes
- Change in shoulder function as assessed by the American Shoulder and Elbow Surgeons Shoulder Score (ASES)(baseline, 4weeks, 3 months, 6 months 9 months, and 12 months)
- Change in range of motion as assessed by the Passive Range of Motion (PROM) assessment using a goniometer(baseline, 4weeks, 3 months, 6 months 9 months, and 12 months)
- Change in pain intensity as assessed by the Visual Analog Scale (VAS)(baseline, 4weeks, 3 months, 6 months 9 months, and 12 months)
- Change in pain and functional disability as assessed by the Shoulder Pain and Disability Index (SPADI)(baseline, 4weeks, 3 months, 6 months 9 months, and 12 months)
Study Sites (2)
Loading locations...
Similar Trials
Completed
N/A
Pilot Study to Evaluate the Safety and the Efficacy of the Matrix and Cells Obtained by the AmeaCell® Device and Intended for the Filling of Wrinkles on the Face.Skin AgingNCT03529292Symbioken23
Completed
N/A
Gene-activated Bone Substitute for Maxillofacial Bone RegenerationBone CystsBone AtrophyBone DeformityBone FractureBone LossTooth LossNCT03076138Histograft Co., Ltd.20
Recruiting
Phase 1
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Majorβ-thalassemiaNCT06465550Shanghai BDgene Co., Ltd.9
Unknown
Phase 1
Autologous Bulbar Olfactory Ensheathing Cells and Nerve Grafts for Treatment of Patients With Spinal Cord TransectionSpinal Cord Injury at C5-Th10 Level With Complete LesionSpinal Cord TransectionNCT03933072Nicholls Spinal Injury Foundation2
Completed
Phase 1
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple SclerosisAutoimmune DiseasesImmune System DiseasesDemyelinating DiseasesNervous System DiseasesDemyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNCT01056471Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud30